Clinical trials: HER2 Low
Breast Cancer With Low Expression of HER2
ARX788 in Breast Cancer With Low Expression of HER2
A Phase 2 Study of ARX788 in unresectable and/or metastatic breast cancer with low expression of HER2.
- Trial name
- NCT05018676
- Testing
- ARX788
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Fudan University
Breast Cancer
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
The purpose of this study is to find out if there is a benefit of adding Herceptin (trastuzumab) to standard chemotherapy in this type of breast cancer.
- Trial name
- NCT00944047
- Testing
- nab-paclitaxel, trastuzumab, Doxorubicin
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Kansas Medical Center
Breast Neoplasms, Breast Cancer
Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer
The purpose of this study is to determine the safety and efficacy of the investigational trifunctional anti-Her-2/neu x anti-CD3 antibody ertumaxomab as treatment for hormone therapy refractory Her-2/neu 1+ or 2+ expressing…
- Trial name
- IV REXBC 02 (NCT00351858)
- Testing
- ertumaxomab
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Neovii Biotech